Related Experiment Video

Updated: May 29, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Polymorphisms contribution to the determination of significant risk of specific toxicities in multiple myeloma

M Almási1, S Sevcíková, H Sváhová

  • 1Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Hematology, University Hospital Brno, Czech Republic.

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|September 20, 2011
PubMed

Insights

Genetic analysis of single nucleotide polymorphisms (SNPs) can personalize multiple myeloma (MM) treatments. This approach aims to improve drug effectiveness and minimize toxicity for patients with this incurable blood cancer.

Area of Science:

  • Genomics
  • Oncology
  • Pharmacogenetics

Background:

  • Multiple myeloma (MM) treatment has improved but remains challenging due to frequent relapses.
  • Individual genetic variations significantly influence patient response, drug sensitivity, and toxicity.
  • Personalized medicine strategies are crucial for optimizing MM therapy.

Purpose of the Study:

  • To explore the potential of detecting and evaluating genetic polymorphisms linked to treatment toxicity in multiple myeloma patients.
  • To highlight the role of single nucleotide polymorphisms (SNPs) in understanding individual variability in MM treatment outcomes.

Main Methods:

  • Genomic analysis focusing on single nucleotide polymorphisms (SNPs).
  • Evaluation of genetic variations associated with drug toxicity.
  • Application of SNP analysis for personalized treatment strategies.

Main Results:

  • Single nucleotide polymorphism (SNP) analysis offers a method to identify genetic factors influencing MM treatment toxicity.
  • This genomic approach can provide insights for tailoring treatments to individual patients.
  • Potential for improving therapeutic effectiveness while reducing adverse effects.

Conclusions:

  • Genetic variability, specifically through SNP analysis, plays a key role in MM treatment outcomes.
  • Detecting and evaluating relevant polymorphisms can guide personalized therapeutic decisions.
  • This strategy holds promise for enhancing treatment efficacy and minimizing toxicity in multiple myeloma care.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...